144 related articles for article (PubMed ID: 7858182)
1. Humanization of the murine anti-human CD3 monoclonal antibody OKT3.
Adair JR; Athwal DS; Bodmer MW; Bright SM; Collins AM; Pulito VL; Rao PE; Reedman R; Rothermel AL; Xu D
Hum Antibodies Hybridomas; 1994; 5(1-2):41-7. PubMed ID: 7858182
[TBL] [Abstract][Full Text] [Related]
2. Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression.
Woodle ES; Thistlethwaite JR; Jolliffe LK; Zivin RA; Collins A; Adair JR; Bodmer M; Athwal D; Alegre ML; Bluestone JA
J Immunol; 1992 May; 148(9):2756-63. PubMed ID: 1533410
[TBL] [Abstract][Full Text] [Related]
3. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
Cole MS; Anasetti C; Tso JY
J Immunol; 1997 Oct; 159(7):3613-21. PubMed ID: 9317161
[TBL] [Abstract][Full Text] [Related]
4. In vitro characterization of five humanized OKT3 effector function variant antibodies.
Xu D; Alegre ML; Varga SS; Rothermel AL; Collins AM; Pulito VL; Hanna LS; Dolan KP; Parren PW; Bluestone JA; Jolliffe LK; Zivin RA
Cell Immunol; 2000 Feb; 200(1):16-26. PubMed ID: 10716879
[TBL] [Abstract][Full Text] [Related]
5. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.
Alegre ML; Collins AM; Pulito VL; Brosius RA; Olson WC; Zivin RA; Knowles R; Thistlethwaite JR; Jolliffe LK; Bluestone JA
J Immunol; 1992 Jun; 148(11):3461-8. PubMed ID: 1534096
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.
Le Gall F; Reusch U; Moldenhauer G; Little M; Kipriyanov SM
J Immunol Methods; 2004 Feb; 285(1):111-27. PubMed ID: 14871540
[TBL] [Abstract][Full Text] [Related]
7. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.
Alegre ML; Tso JY; Sattar HA; Smith J; Desalle F; Cole M; Bluestone JA
J Immunol; 1995 Aug; 155(3):1544-55. PubMed ID: 7636216
[TBL] [Abstract][Full Text] [Related]
8. Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions.
Li B; Wang H; Dai J; Ji J; Qian W; Zhang D; Hou S; Guo Y
Immunology; 2005 Dec; 116(4):487-98. PubMed ID: 16313362
[TBL] [Abstract][Full Text] [Related]
9. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
[TBL] [Abstract][Full Text] [Related]
10. Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.
Silva HM; Vieira PM; Costa PL; Pimentel BM; Moro AM; Kalil J; Maranhão AQ; Coelho V; Brigido MM
Immunol Lett; 2009 Aug; 125(2):129-36. PubMed ID: 19573559
[TBL] [Abstract][Full Text] [Related]
11. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
Alegre ML; Peterson LJ; Xu D; Sattar HA; Jeyarajah DR; Kowalkowski K; Thistlethwaite JR; Zivin RA; Jolliffe L; Bluestone JA
Transplantation; 1994 Jun; 57(11):1537-43. PubMed ID: 8009586
[TBL] [Abstract][Full Text] [Related]
12. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro.
Cole MS; Stellrecht KE; Shi JD; Homola M; Hsu DH; Anasetti C; Vasquez M; Tso JY
Transplantation; 1999 Aug; 68(4):563-71. PubMed ID: 10480417
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.
Richards J; Auger J; Peace D; Gale D; Michel J; Koons A; Haverty T; Zivin R; Jolliffe L; Bluestone JA
Cancer Res; 1999 May; 59(9):2096-101. PubMed ID: 10232594
[TBL] [Abstract][Full Text] [Related]
14. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
[TBL] [Abstract][Full Text] [Related]
15. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Pardridge WM
Biotechnol Bioeng; 2007 Feb; 96(2):381-91. PubMed ID: 16937408
[TBL] [Abstract][Full Text] [Related]
16. Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin.
He XY; Xu Z; Melrose J; Mullowney A; Vasquez M; Queen C; Vexler V; Klingbeil C; Co MS; Berg EL
J Immunol; 1998 Jan; 160(2):1029-35. PubMed ID: 9551944
[TBL] [Abstract][Full Text] [Related]
17. Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A.
Pulito VL; Roberts VA; Adair JR; Rothermel AL; Collins AM; Varga SS; Martocello C; Bodmer M; Jolliffe LK; Zivin RA
J Immunol; 1996 Apr; 156(8):2840-50. PubMed ID: 8609403
[TBL] [Abstract][Full Text] [Related]
18. A humanized monovalent CD3 antibody which can activate homologous complement.
Routledge EG; Lloyd I; Gorman SD; Clark M; Waldmann H
Eur J Immunol; 1991 Nov; 21(11):2717-25. PubMed ID: 1834468
[TBL] [Abstract][Full Text] [Related]
19. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
Wu H; Nie Y; Huse WD; Watkins JD
J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
[TBL] [Abstract][Full Text] [Related]
20. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1.
Werther WA; Gonzalez TN; O'Connor SJ; McCabe S; Chan B; Hotaling T; Champe M; Fox JA; Jardieu PM; Berman PW; Presta LG
J Immunol; 1996 Dec; 157(11):4986-95. PubMed ID: 8943405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
